Target Therapy for Hepatocellular Carcinoma.
10.7599/hmr.2012.32.2.118
- Author:
Seung Kew YOON
1
Author Information
1. Division of Hepatology-Gastroenterology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. yoonsk@catholic.ac.kr
- Publication Type:Review ; Clinical Trial
- Keywords:
Carcinoma, Hepatocellular;
Molecular Targeted Therapy;
Sorafenib;
Signal Transduction
- MeSH:
Alanine;
Carcinoma, Hepatocellular;
Membranes;
Molecular Targeted Therapy;
Niacinamide;
Phenylurea Compounds;
Receptors, Platelet-Derived Growth Factor;
Receptors, Vascular Endothelial Growth Factor;
Signal Transduction;
Sirolimus;
Triazines;
Everolimus
- From:Hanyang Medical Reviews
2012;32(2):118-125
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Hepatocellular carcinoma (HCC) is a highly malignant tumor that has limited treatment options in its advanced state. The efficacy of current anti-cancer chemotherapy in advanced HCC has not been satisfactory, and the management of HCC remains a major challenge for physicians. However, recent advancement in our understanding of the molecular mechanisms underlying carcinogenesis has provided novel targets in key signaling pathways for tumor development. Recently, Sorafenib (Nexavar), a multi-kinase inhibitor targeting membrane receptors involved in angiogenic and mitogenic intra-cellular signaling including Raf, vascular endothelial growth factor receptor (VEGFR), and platelet-derived growth factor receptors (PDGFR), has been approved worldwide as a new target agent for HCC, and subsequent clinical trials of newly developed molecular target agents such as Brivanib and Everolimus are being conducted globally. In the near future, continued research will lead to the identification of additional molecular targets in HCC and lead to treatments with enhanced efficacy and improved tolerability.
